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ABSTRACT 
  
Identification of peptides presented in major histocompatibility complex (MHC) class I 
molecules after viral infection is of strategic importance for vaccine development. Until 
recently, mass spectrometric identification of virus-induced peptides was based on 
comparative analysis of peptide pools isolated from uninfected and virus-infected cells. Here 
we report on a powerful strategy aiming at the rapid, unambiguous identification of naturally 
processed MHC class I-associated peptides, which are induced by viral infection. The 
methodology, stable isotope tagging of epitopes (SITE), is based on metabolic labeling of 
endogenously synthesized proteins during infection. This is accomplished by culturing virus-
infected cells with stable isotope-labeled amino acids that are expected to be anchor residues 
(i.e. residues of the peptide that have amino acid side chains that bind into pockets lining the 
peptide-binding groove of the MHC class I molecule) for the human leukocyte antigen allele of 
interest. Subsequently these cells are mixed with an equal number of non-infected cells, which 
are cultured in normal medium. Finally peptides are acid-eluted from immunoprecipitated 
MHC molecules and subjected to two-dimensional nanoscale LC-MS analysis. Virus-induced 
peptides are identified through computer-assisted detection of characteristic, binomially 
distributed ratios of labeled and unlabeled molecules. Using this approach we identified novel 
measles virus and respiratory syncytial virus epitopes as well as infection-induced self-
peptides in several cell types, showing that SITE is a unique and versatile method for 
unequivocal identification of disease-related MHC class I epitopes.  
The adaptive immune response to virus infections is characterized by the generation of CD8+ 
cytotoxic T lymphocytes (CTLs),1 which recognize peptides presented by MHC class I 
molecules of infected cells. The MHC class I molecules display peptides from proteins 
expressed inside the cell that are usually generated in the classical proteasomal pathway. 
Under physiological conditions these peptides are derived from self-proteins. During viral 
infection, the MHC class I display of peptides is affected due to changes in host protein 
expression and as a result of the production of viral proteins (1, 2). Identification and 
quantification of such altered MHC-peptide expression is a goal as part of a new field of 
research referred to as immunoproteomics and is of strategic importance for vaccine 
development (1, 3–5). The analytical challenge lies in the discrimination between the few 
disease-related peptides among a majority of nondisease-related peptides (6). Several 
strategies have been developed to explore changes in the MHC-associated peptide display on 
antigen-presenting cells. These analyses are generally based on the isolation of the MHC-
peptide complexes, acid elution of the bound peptides from the MHC molecules followed by 
analysis using LC and MS as pioneered by Hunt et al. (7) and adapted for various purposes 
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by other groups (4, 8–11). We successfully used the mass spectrometric method to identify 
novel MHC class I-restricted viral epitopes by subtractive analysis of peptide pools isolated 
from virus-infected and control cells (9). This comparative method, however, needs 
meticulous parallel sample processing of the infected and control peptide batches, and 
differences in peptide recovery as well as chromatographic retention and stability between 
uninfected and infected peptide samples cannot be excluded. This has limited the use of 
subtractive analysis and might have led to the failure to identify viral epitopes (8, 10).  
The importance of CD8+ T cells in the recovery from respiratory infections such as measles 
virus (MV) or respiratory syncytial virus (RSV) is generally acknowledged (12, 13). Although 
healthy children clear these infections in 7–21 days, children with disorders in the CTL 
response may suffer from complications after MV (13, 14) or RSV infection (15). Interestingly 
findings in humans as well as in animal models suggested that CD8+ T cells may confer 
protective immunity to RSV infection but may also induce enhanced pulmonary pathology 
(16–18). Hence the ability to mount a CD8+ T cell response is considered a major condition for 
protective immunity to MV or RSV infection but is also associated with increased pulmonary 
disease in the case of RSV. As only limited knowledge is available about the target epitopes 
for these viruses expressed in frequently occurring HLA types such as HLA-A*0201 and HLA-
B7 (13, 19), further elucidation of the naturally processed and MHC class I-presented viral 
epitopes may benefit vaccine development as well as analysis of the CTL response.  
Here we set out to develop a new strategy named stable isotope tagging of epitopes (SITE) 
for the facilitated identification of virus-induced, MHC class I-presented peptides by mass 
spectrometry. Protein expression in infected cells was performed in the presence of stable 
isotope-labeled amino acids, which enabled detection of virus-induced peptides by LC-MS. 
The analysis was done on one single peptide sample derived from a mixture of infected and 
uninfected cells. We applied SITE to detect virally induced epitopes for the common HLA 
class I alleles A*0201 and B7. In addition to a renewed survey of HLA-A*0201-presented MV-
derived epitopes as detected by comparative analysis earlier (9), we used the technique to 
identify and semiquantify RSV epitopes and RSV-induced self-epitopes for HLA-A*0201 and 
HLA-B7. The application of SITE resulted in the identification and semiquantification of several 
novel naturally processed viral epitopes and virus-induced self-epitopes, which might add to 
our understanding of the induction and maintenance of antiviral immunity.  
EXPERIMENTAL PROCEDURES 
  
Cell Culturing and Measles Virus Infection— 
An HLA-A*0201 homozygous Epstein-Barr virus-transformed B-lymphoblastoid cell line was 
cultured in complete RPMI 1640 medium (Invitrogen) supplemented with 5% heat-inactivated 
fetal bovine serum (FBS, HyClone) in a humidified atmosphere with 5% CO2 at 37 °C to a total 
number of 3·109 cells. One-half of this batch was harvested and infected with plaque-purified 
MV (Edmonston B strain) at a multiplicity of infection (m.o.i.) of 0.5 for 2 h. These cells were 
subsequently incubated for 40 h in RPMI 1640 medium without l-leucine and l-methionine 
(Invitrogen), which was supplemented to obtain standard concentrations of l-leucine and l-
methionine with 50% 5,5,5-l-[2H3]leucine (Cambridge Isotope Laboratories), 50% unlabeled l-
leucine, 50% methyl-[13C1]methyl-l-[2H3]methionine, 50% unlabeled l-methionine (all from 
Sigma), and 5% FBS. RPMI 1640 medium containing 100% of the unlabeled amino acids and 
5% FBS was used for the uninfected cells. Both control and infected batches were harvested, 
washed three times with PBS, and equally (i.e. 1.5·109 cells from each batch) mixed. The cells 
were pelleted, snap frozen, and stored at –70 °C until peptide isolation and analysis.  
Cell Culturing and RSV Infection— 
Peripheral blood mononuclear cells (PBMCs) from an HLA-A*0201, -B7, -Cw7, -DQ1, -DR2 
homozygous donor were isolated after leukapheresis by centrifugation of buffy coat cells on 
Ficoll-Hypaque (Amersham Biosciences). Monocyte-derived, immature dendritic cells (iDCs) 
were cultured according to a procedure by Sallusto and Lanzavecchia (20). Briefly 0.6·109 
PBMCs were seeded at 5·106 PBMCs/ml in 150-mm tissue culture dishes (Costar) in 
Iscove’s modified Dulbecco’s medium (Invitrogen) supplemented with 1% FBS at 37 °C at 5% 
CO2 in a humidified incubator for 2 h. After removal of the non-adherent fraction, adherent 
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cells were cultured for 6 days in medium containing recombinant human granulocyte-
macrophage colony-stimulating factor (500 units/ml, PeproTech) and recombinant human 
interleukin-4 (250 units/ml, Strathman Biotech). Culture medium and growth factors were 
refreshed on day 4. On day 6, iDCs were pooled to obtain two batches containing equal 
numbers of cells. One batch was infected with plaque-purified human RSV (RSV-A2 number 
VR-1302, ATCC) at a m.o.i. of 5 for 3 h and cultured in Iscove’s 1% FBS fortified with 50% 
each of l-[13C6]leucine, l-[13C5,15N1]methionine, and l-[13C5,15N1]valine (all from Cambridge 
Isotope Laboratories). These amino acids represent 74% of the anchor residues at position 2 
(P2) and 77% at P9 for HLA-A*0201 and 10 and 90% of the anchor residues at P2 and P9 for 
HLA-B7, respectively (21). Hence labeling of the majority of the virally induced peptides bound 
to these HLA alleles was expected. A similar RPMI 1640 medium supplemented with 
equimolar amounts of the unlabeled amino acids l-leucine, l-methionine, and l-valine (all from 
Sigma) was utilized for the uninfected cells. Hereafter cells were further cultured and 
maturated in the continuous presence of growth factors (granulocyte-macrophage colony-
stimulating factor, 250 units/ml; interleukin-4, 125 units/ml) and 20 ng/ml lipopolysaccharide 
(Salmonella abortus equi, Sigma). On day 8, i.e. 48 h after infection, >95% of the infected 
dendritic cells (DCs) showed RSV-specific staining and maturation by flow cytometric analysis 
(data not shown). Both control and infected batches were harvested, washed three times with 
PBS, and equally mixed (i.e. 1.3·107 cells from each batch, which is within the usual range of 
DCs that are generated from PBMCs in this protocol (22)). The cell mixture was pelleted, snap 
frozen, and stored at –70 °C until peptide isolation and analysis.  
Human HLA-A*0201 homozygous epithelial cells (Caco-2, number HTB-37, ATCC) cultured in 
Iscove’s supplemented with 10% FBS were treated similarly to iDCs on day 6. Infection of 
1.3·108 cells was performed at a m.o.i. of 1 for 3 h in Iscove’s 1% FBS. Cells were further 
cultured for 48 h in Iscove’s 1% FBS supplemented with 50% of the labeled (infected batch) or 
100% of the unlabeled (control batch) amino acids.  
Isolation of HLA-bound Peptides— 
HLA-associated peptides were isolated as described by Hunt et al. (7). Briefly the cells were 
lysed in a Tris·HCl buffer containing 1% CHAPS (Roche Applied Science) and protease 
inhibitors at pH = 8.0. After centrifugation, the supernatant was passed in succession over 
three CNBr-activated Tris-blocked Sepharose columns: the first non-immunoglobulin-coupled 
(i.e. preclear), the second coupled with normal mouse immunoglobulin (i.e. clear), and the 
third coupled with HLA-specific mouse antibodies: BB7.2 or B1.23.2 for HLA-A*0201 and 
HLA-B7, respectively. The HLA-peptide complexes were eluted with 10% acetic acid and 
passed over a 10-kDa molecular mass cutoff membrane filter. The filtrate was concentrated to 
10 µl using vacuum centrifugation and subsequently reconstituted in 5% formic acid and 5% 
dimethyl sulfoxide to a final volume of 100 µl and stored at –70 °C until analysis.  
Microcapillary Strong Cation Exchange (SCX) Fractionation— 
Half of the total MHC extract was fractionated using SCX chromatography (23–26). First the 
MHC sample was loaded onto a HypercarbTM trapping column (5-mm length x 200-µm internal 
diameter, packed in house) at a flow rate of 5 µl/min with 0.1 m acetic acid. The column 
effluent was directed to waste. After 4 min, the trapping column was switched in series with an 
SCX column (polysulfoethyl aspartamide, 12-cm length x 200-µm internal diameter, packed in 
house), and the peptides were eluted to the SCX column by injection of a 1-µl plug of 50% 
acetonitrile in 0.1 m acetic acid. Finally a linear salt gradient was run to 500 mm KCl in 35% 
acetonitrile at a column flow rate of 2 µl/min. A total number of 26 fractions (2 min each) were 
collected and dried using a vacuum centrifuge. The fractions were stored at –70 °C until 
analysis.  
Nanoscale Reversed Phase LC and MS (Nanoscale LC-MS)— 
The individual SCX fractions were reconstituted in 20 µl of 5% formic acid and 5% dimethyl 
sulfoxide, fortified with two standard peptides angiotensin-III and oxytocin, each at a 
concentration level of 200 amol/µl, and analyzed using a nanoscale LC-MS system exactly as 
described earlier (27). The system comprises an AquaTM C18 trapping column (15-mm length x 
100-µm internal diameter, 5-µm particle size, 200-Å pore size, Phenomenex®) and an Aqua 
C18 analytical column (25-cm length x 50-µm internal diameter, 5-µm particle size, 125-Å pore 
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size). The analytical column was butt-connected to a gold-coated spray tip (15-mm length x 
25-µm internal diameter) manually tapered to 5-µm internal diameter. A 5-µl portion of the 
SCX fraction was loaded onto the trapping column at a flow rate of 3 µl/min with 0.1 m acetic 
acid for 15 min while directing the column effluent to waste. The trapping column was then 
switched in line with the analytical column, and a linear gradient to 60% acetonitrile with 0.1 m 
acetic acid was run at a column flow rate of 125 nl/min. A home-built sheathless electrospray 
interface was used mounted on a Q-TOF Ultima API mass spectrometer (Waters). The mass 
spectrometer was operated in V-mode at a resolving power of 10,000. Full scan mass spectra 
were acquired in continuum mode at a scan speed of 1 s/scan. Candidate epitopes were 
identified by targeted CID MS/MS analyses using identical chromatographic conditions and on 
the same Q-TOF Ultima API mass spectrometer operated at optimized collision energy.  
Automated Data Processing— 
All instrument LC-MS data files were converted to the NetCDF file format and subsequently 
imported into the MATLAB® technical computing environment (The MathWorks, Inc.). 
Essential mass spectral information (defined by the data arrays "mass_values" and 
"intensity_values") was extracted and used for the search algorithm. First simulated isotope 
patterns were calculated based on (i) the stable isotope labels used, (ii) the natural occurrence 
of these stable isotopes, (iii) the presumed maximum number of labeled amino acids 
incorporated in the epitope, (iv) the experimental design, and (v) the charge state of the ions 
involved. Each individually simulated isotope pattern was mathematically moved along the 
mass axis of the MS spectrum. Matching isotope clusters were selected for MS/MS analysis in 
which the unlabeled isomer within an isotope cluster was chosen as the parent ion. The 
resolution values for quadrupole 1 (i.e. low mass resolution value and high mass resolution 
value) were set to 10 to prevent including the first labeled isomer in the CID spectrum. 
Analyses using a larger selection window were indicated in the CID spectra where 
appropriate.  
Identification of Candidate Epitopes— 
The acquired MS/MS spectra were analyzed using MassLynx version 4.0 SP1 software and 
processed by background subtraction (first polynomial order below 45% curve), spectrum 
smoothing (Savitzky Golay, two smooths at ±6 channels), and deconvolution (MaxEnt3, using 
automatic peak width determination). The resulting MS/MS spectra were manually interpreted 
to compose a sequence tag (28). This tag was submitted to the on-line search algorithm 
MASCOT at www.matrixscience.com for peptide identification utilizing the National Center for 
Biotechnology Information non-redundant (NCBInr) protein database (versions between 
20040113 and 20041201) within the taxonomy parameter Homo sapiens and viruses. No 
enzyme specificity was selected. The peptide and MS/MS tolerances were set to ±0.2 and 
±0.3 Da, respectively, for the high abundance candidates. For the low abundance epitopes 
these tolerances were ±0.4 and ±0.8 Da, respectively. Final validation of each of the peptide 
sequences was based on the following: (i) equal molecular masses of the natural epitope and 
the proposed sequence, (ii) matching the total number of labeled amino acids (i.e. Leu, Met, 
or Val) contained within the epitope with that in the proposed peptide sequence (this number 
was deduced from the mass spectral isotope distribution in the MS spectra), (iii) mutual 
comparison of the MS/MS spectra of the natural processed epitope and its synthetic 
analogue, and (iv) comparison of the chromatographic retention times of the epitope and its 
synthetic analogue applying similar instrumental conditions.  
Semiquantification of Epitopes— 
Relative response factors (RRf) were calculated by the intensity-amount ratio of the synthetic 
analogue of the identified epitope and divided by the mean of the intensity-amount ratios of 
the standard peptides angiotensin-III and oxytocin. These RRf values were subsequently used 
for the semiquantification of the numbers of natural epitopes present in the pooled cell batch.  
The expression level of each epitope was determined for viral and self-peptides as follows.  
• Viral epitopes were only generated in the infected cell batch. The expression level 
was therefore calculated as the quotient of the number of epitope molecules and the 
number of infected cells.  
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• Up-regulated self-peptides might originate from both the infected and control cells. 
The degree of up-regulation of the self-peptides on the infected cells was derived from 
a curve defining the relation between the intensity ratio M/[M + ] (Fig. 1B) versus the 
degree of up-regulation for a particular epitope.  
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FIG. 1. Schematic representation of the experimental design for the allocation and 
identification of virally induced MHC class I-associated peptides using the SITE 
strategy. A, the antigen-presenting cells are grown in normal culture medium. One half of the 
cell batch is virus-infected in culture medium fortified with 50% of the labeled (i.e. heavy) and 
50% of the unlabeled (i.e. light) amino acids, known as the HLA-specific anchor residues. 
These amino acids are incorporated in the endogenously synthesized proteins at a 50% 
probability, visualized by the half-filled circles (white = incorporation of a light amino acid; 
black = incorporation of a heavy amino acid). Here the identification of peptides containing 
two heavy amino acids is shown. After infection, the non-infected control cell batch, cultured 
in unlabeled light medium, is pooled with an equal number of the infected cells. By pooling the 
cell batches, the binomial isomer distributions of non-induced HLA-presented self-epitopes 
are affected (left panel), whereas the heavy/light distributions of peptides exclusively 
produced during viral infection remain unaltered (right panel) as these peptides are not 
present in the control batch. HLA-associated peptides are then isolated by immunoaffinity 
purification and acid elution and finally fractionated into 26 fractions by SCX chromatography. 
Each fraction is analyzed by nanoscale LC-MS analysis on a high resolution mass 
spectrometer. A search algorithm is used to allocate candidate MV- or RSV-associated 
epitopes, which are identified by targeted nanoscale LC-MS/MS analysis. B, theoretical 
isotope distributions of self-peptides containing two heavy amino acids from pooled 
uninfected and virus-infected cells grown in 100% light and 50% light, 50% heavy medium, 
respectively. The distributions are shown for an unaltered expression of the self-peptides and 
for a 2-, 5-, 20-, and 100-fold up-regulated expression after virus infection. 
Peptide Synthesis— 
Synthetic peptides were prepared by Fmoc (N-(9-fluorenyl)methoxycarbonyl) solid phase 
synthesis using a SYRO II simultaneous multiple peptide synthesizer (MultiSyntech GmbH, 
Witten, Germany).  
RESULTS AND DISCUSSION 
  
The general strategy of SITE is shown in Fig. 1A. A control batch of cells is cultured in normal 
"light" medium, and another is grown in modified medium after viral infection and containing 
50% light and 50% heavy HLA-binding anchor amino acids using the stable isotopes of 
carbon, hydrogen, or nitrogen. This allows all self- and viral proteins synthesized in the virus-
infected batch to incorporate these "heavy" residues at a 50% probability, resulting in a 
binomial distribution pattern, before being processed in the MHC class I pathway. Equal 
numbers of cells from both batches are pooled prior to isolation of the MHC-associated 
peptides. By pooling the cell batches, the binomial isomer distributions of stably expressed 
self-epitopes are affected. However, the heavy/light distributions of peptides originating from 
proteins exclusively produced during viral infection remain unaltered as these peptides are not 
present in the control batch. After elution of the peptides from the HLA class I molecules, SCX 
chromatography is used in an off-line mode of operation to highly fractionate the sample. A 
portion of each fraction is then subjected to nanoscale LC-MS analysis to search for virally 
induced peptides (27). This allocation is based on the computer-assisted recognition of the 
binomially distributed mass spectral isotope patterns of peptides containing one or more 
labeled amino acid residues. Sequence information of the selected epitopes is obtained by 
targeted nanoscale LC-MS/MS analysis on the remaining portion of the SCX fraction.  
SITE allowed the identification of known and novel viral epitopes and virus-induced self-
peptides in the MHC class I-associated peptide display of HLA-A*0201 homozygous B cells 
after MV infection (Table I). During the 40-h infection period, the culture medium of the MV-
infected cell batch was enriched with 50% of both l-[2H3]leucine and l-[13C1,2H3]methionine 
(mass increments of 3 and 4 Da, respectively, as compared with their unlabeled analogues), 
known as HLA-A*0201-binding anchors. Fig. 2A illustrates a typical mass spectral isotope 
distribution of a candidate infection-related peptide showing ions at M + 3 and M + 6 Da, 
which indicates that the epitope contains two leucine residues. Targeted MS/MS analysis 
revealed the amino acid sequence as GLASFILTI, which originates from the nucleocapsid 
protein of MV. This peptide has not been reported earlier as a naturally processed and 
presented MV epitope. In addition to GLASFILTI, two other known MV epitopes were allocated 
and identified with the SITE strategy, including the highly abundant KLWESPQEI (9). 
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Furthermore SITE also revealed a highly up-regulated MHC class I-presented self-peptide, 
TLIDLPGITRV (Fig. 3), that stems from the -interferon-induced protein MxA. This protein has 
a direct antiviral function against RNA viruses (29). Interestingly up-regulated expression of 
the same MxA-derived epitope was also detected on RSV-infected DCs (see below), 
reflecting a shared component in the host antiviral response.  
TABLE I HLA class I epitopes associated with MV or RSV infections that were identified using 
the SITE strategy  
Expression of the earlier described 'stress' epitope ILDKKVEKV originating from the self-
protein heat shock protein 90ß-(570–578) (Hsp90ß-(570–578)) was detected in this study on 
HLA-A*0201 of MV-infected B cells. However, it was not significantly up-regulated, confirming 
earlier reports on the variedly increased expression of this epitope after MV infection (37). 
calc, calculated; exp, experimental; MAP, mitogen-activated protein; NK, natural killer; N.Q., 
not quantified.  
HLA allele Host cell Peptide sequence MH+calc MH+exp Abundancea Source protein 
NCBI 
accession 
number Function 
 
   Da Da ·103 
copies/cell 
   
MV         
    Viral         
        A*0201 B cell KLWESPQEI 1129.6 1129.8 50 Nonstructural C 
protein 
P03424 Regulation of 
transcription 
        A*0201 B cell QLPEATFMV 1035.5 1035.7 N.Q. Matrix protein P06942 Virion 
assembly and 
budding 
        A*0201 B cell GLASFILTI 934.6 934.8 0.1 Nucleoprotein P04851 Replication of 
viral genome 
    Self         
        A*0201 B cell TLIDLPGITRV 1197.7 1197.7 25 (6) Interferon-
regulated 
resistance GTP-
binding protein 
(MxA) 
P20591 Inhibition of 
RNA virus 
replication 
        A*0201 B cell SLIGHLQTL 981.6 981.8 30 (4) Dual specificity 
protein 
phosphatase 5 
Q16690 Antagonize 
members of 
the MAP 
kinase 
superfamily 
RSV         
    Viral         
        A*0201 DC KLIHLTNAL 1022.6 1022.8 2 Nonstructural-1 
protein 
P04544 Possibly role 
in RNA 
synthesis 
        A*0201 Epithelial 
cell 
KLIHLTNAL 1022.6 1022.7 0.1 Nonstructural-1 
protein 
P04544 Possibly role 
in RNA 
synthesis 
        B7 DC KARSTPVTL 972.6 972.7 5 Fusion protein P03420 Fusion of viral 
envelope with 
host cell 
    Self         
        A*0201 DC FIIQGLRSV 1032.6 1032.7 10 (2) HLA class II 
DQ1 -chain 
HLA-DQA1*05; 
HLA-DQ*06 
P01906P01907 Peptide 
presentation 
to CD4+ T 
cells 
        A*0201 DC IQHDLIFSL 1085.6 1085.7 1 (0.3) Hypoxia-
induced factor-
1  (HIF-1 ) 
Q16665 Transcriptional 
regulator of 
several genes 
        A*0201 DC TLIDLPGITRV 1197.7 1197.8 15 (1) Interferon-
regulated 
resistance GTP-
binding protein 
(MxA) 
P20591 Inhibition of 
RNA virus 
replication 
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        B7 DC APLRPAAPGQTPL 1288.7 1288.9 0.2 (0.01) Proline-rich 
nuclear receptor 
coactivator-1 
(B4-2 protein) 
Q12796 Activator of 
gene 
transcription 
        B7 DC AVHPSGVAL 850.5 850.6 2 (0) Interferon-
inducible 
protein-15K (IFI-
15K) 
NM_005101 NK cell 
proliferation 
and non-MHC-
restricted 
cytotoxicity 
        B7 DC KPYPLHRIKL 1264.8 1265.0 3 (0.5) Asparaginyl 
endopeptidase 
(AEP) 
Q99538 Processing of 
proteins for 
MHC class II 
antigen 
presentation in 
the lysosomal 
or endosomal 
system 
         
        B7 DC SPAEPSVYATL 1134.6 1134.6 2 (0.5) Leukocyte 
immunoglobulin-
like receptor 5 
(LIR-5) 
Q8NHJ6 Modulation of 
CD4+ T cell 
function 
    HLA 
leader 
sequences 
        
        B7 DC APRTLVLLL 995.7 995.7 35 (3) HLA class I A*2 
precursor 
P01892 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC APRTVLLL 882.6 882.7 1 (0.1) HLA class I B*7 
precursor 
P01889 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC APRTVLLLLSA 1153.7 1153.9 20 (1) HLA class I B*7 
precursor 
P01889 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC APRTVLLLLSAA 1224.8 1224.9 2 (0.1) HLA class I B*7 
precursor 
P01889 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC LVMAPRTVL 999.6 999.7 10 (1) HLA class I B*7 
precursor 
P01889 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC RVMAPRALL 1026.6 1026.8 50 (3) HLA class I 
Cw*7 precursor 
P10321 Peptide 
presentation 
to CD8+ T 
cells 
        B7 DC APRALLLLL 979.7 979.8 100 (7) HLA class I 
Cw*7 precursor 
P10321 Peptide 
presentation 
to CD8+ T 
cells 
 
A
 The values represent the copy numbers of the peptides on the infected cells and on the 
non-infected cells (in parentheses).  
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FIG. 2. Typical mass spectral isotope distribution patterns of infection-associated MHC 
class I epitopes using the SITE strategy. The upper trace (A) represents the singly charged 
MV-originating epitope GLASFILTI. Without prior knowledge of the peptide sequence, it was 
deduced from the M + 3 incremental sequence in the MS spectrum that this peptide contains 
two leucine residues. Although these residues were expected to incorporate in a binomial 
distribution during the infection, the obtained MS spectrum shows that this is slightly biased in 
favor of the unlabeled isomers. This can be attributed to either small differences in 
noncovalent binding characteristics between the unlabeled and labeled isomers and the MHC 
molecule or to recycling of nonlabeled amino acid residues from the existing protein pool. The 
search algorithm was adapted for this bias, resulting in an accurate calculation of the 
theoretical isotope distribution (inset A1). The lower trace (B) shows the experimental and 
theoretical (inset B1) isotope distributions of the RSV infection-associated self-peptide 
RVMAPRALL ([MH2]2+ = 513.87 Da) having an incremental sequence of = +3 Da for each of 
the four labeled residues present in the peptide. A peptide ([MH2]2+ = 520.36 Da, containing 
two labeled residues) not related to the infection interfered with this isotope cluster, 
introducing an additional series of ions with = +3 Da, which is illustrated by its theoretical 
isotope pattern (inset B2). 
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FIG. 3. MS/MS spectra of the natural processed and presented self-epitope TLIDLPGITRV 
that is highly up-regulated upon infection with either MV or RSV (middle and bottom trace, 
respectively). The source protein MxA blocks the multiplication of paramyxoviruses such as 
MV and RSV. The MS/MS spectrum of the synthetic analogue (top trace) confirms the identity 
of the natural epitope. The m/z ratio of the precursor ion for TLIDLPGITRV was 599.4 Da (i.e. 
doubly charged ion). The insets show the isotope clusters in the MS spectra for this epitope in 
each of the viral infection systems. For the MV infection, the mass difference for the 
incorporated labeled amino acid (leucine) was +3 Da, resulting in a mass increment of 1.5 Da 
for the doubly charged ions in the MS spectrum. For the RSV infection, the mass difference 
for the incorporated labeled amino acids (leucine and valine) was +6 Da, resulting in a mass 
increment of 3 Da for the doubly charged ions. 
 
Next SITE was applied to identify epitopes induced by RSV for which MHC class I epitope 
expression is largely elusive. Epitope analyses after RSV infection were performed in HLA-
A*0201 homozygous epithelial cells and in monocyte-derived dendritic cells homozygous for 
HLA-A*0201 and HLA-B7. The RSV-infected cells were now cultured in a medium containing 
50% each of the heavy amino acids l-[13C6]leucine, l-[13C5,15N1]methionine, and an additional 
labeled amino acid l-[13C5,15N1]valine. Based on the analysis of the MV epitopes (  = +3 or +4 
Da), we anticipated that an equal and higher mass increment (  = +6 Da) for all labeled 
amino acids would be beneficial for the recognition process. The additional anchor residue 
was applied to ensure a maximal chance of incorporation of at least one labeled amino acid.  
For HLA-A*0201, which is the most frequently occurring Caucasian HLA type, the RSV 
epitope KLIHLTNAL was identified (Fig. 4A), originating from the N terminus of the RSV 
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nonstructural (NS)-1 protein. This peptide was detected both on RSV-infected epithelial cells 
and dendritic cells. DCs are professional antigen-presenting cells and are uniquely capable of 
priming naive CD8+ T cell responses against epitopes they expose. Primed RSV-specific 
CD8+ T cells, in turn, migrate to the respiratory tract and recognize RSV epitopes displayed on 
HLA of infected epithelial cells, which are the primary target for RSV infection. Therefore, 
expression of the HLA-A*0201-restricted epitope KLIHLTNAL on DCs and on epithelial cells 
allows priming of CD8+ T cells that can exert effector function after recognition of cognate 
antigen on RSV-infected epithelial cells. Furthermore HLA-B7 molecules on DCs contained 
the viral epitope KARSTPVTL (Fig. 4B), which originates from the RSV fusion protein (RSV-
F).  
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FIG. 4. MS/MS spectra of the RSV-originating epitopes. A, KLIHLTNAL (doubly charged 
precursor ion m/z 511.9 Da) presented on epithelial cells. Product ions labeled with an 
asterisk are background ion signals that do not originate from KLIHLTNAL (see supplemental 
data). B, KARSTPVTL (doubly charged precursor ion m/z 486.9 Da) presented on DCs and 
their respective synthetic analogues. 
Both KARSTPVTL and KLIHLTNAL are the first naturally processed and presented epitopes 
to be described for RSV. Interestingly CD8+ T cell responses in children who had just 
recovered from severe RSV infection were reported only for the RSV-F and RSV-NS proteins 
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and not for the seven other RSV proteins that were investigated (30). Hence epitope origin of 
naturally processed and presented viral peptides on infected DCs markedly coincides with the 
primary infant CD8+ T cell targets. We therefore suggest that epitope expression on infected 
DCs in young children favors the induction of predominant RSV-NS- and RSV-F-specific CD8+ 
T cell responses.  
In earlier studies based on CD8+ T cell reactivity against a panel of overlapping peptides 
covering the nucleoprotein of RSV, NPKASLLSL was characterized as an HLA-B7 CD8+ T cell 
epitope in adults (19). Natural processing and presentation of this epitope, however, was not 
detected in our experiments, implying that 40 h-infected DCs do not express this epitope 
above the detection limit ( 5 copies/cell) of our LC-MS system. All of the peptides that were 
expressed exclusively after infection and half of the up-regulated peptides could be identified, 
depending on the expression level and the quality of the MS/MS spectrum.  
In total 14 up-regulated self-epitopes were identified after RSV infection of DCs (Table I). 
Interestingly seven of 11 up-regulated self-epitopes presented on HLA-B7 stem from the 
signal peptides of the HLA-A, -B or -C -chain, including several length variants. Although the 
expression of peptides from HLA-derived signal sequences on HLA-A*0201 and HLA-B7 
under physiological conditions was reported earlier (32–34), the increased expression of 
peptides derived from all three class Ia signal sequences as well as the array of length 
variants seem specifically induced by the RSV infection of DCs. The immunologic 
consequence of the dominant expression of these signal sequences is not clear; however, 
enhanced processing and presentation of autoantigens during an infection may prime T cells 
for self-peptides, resulting in autoimmunity (35–37).  
Information on the identity of CTL epitopes is a major asset in identifying targets for vaccine 
development but may also be applied for the development of diagnostic tools to investigate 
the host-immune response after vaccination (38). The use of prediction algorithms to this end 
was shown not to be helpful for screening epitopes in proteins unknown as T cell targets (39). 
Similarly the proteome of most viruses is too large to evaluate the complete T cell response 
by using banks of overlapping peptides. In addition, these strategies do not allow detection of 
post-translational modifications (PTMs). It is estimated that 50–90% of all human proteins are 
post-translationally modified (40). PTMs may therefore result in important changes in the 
immunogenicity of MHC-associated peptides (41–43). Detection of naturally presented 
peptides in MHC class I by SITE enables the recognition of any possible PTM of the epitopes 
introduced during the infection in contrast to the identification of disease-related peptides 
using epitope prediction algorithms. Our experiments, however, did not reveal any PTM of 
MHC class I epitopes following either MV or RSV infection.  
In the last decade, metabolic labeling strategies have become increasingly important in 
quantitative proteomics (31). Recently we successfully used stable isotopes for the 
identification of pathogen-derived epitopes presented in MHC class II molecules (22). Until 
now, no such method has been described for the identification of virally induced MHC class I-
expressed epitopes. The strong advantage of SITE is that the information regarding whether a 
peptide is associated with the infection or not is embedded in one single sample. This enables 
a high degree of fractionation (>25 individual fractions) in two-dimensional separation systems 
for increased separation efficiency. In addition, a single sample strategy is advantageous over 
approaches based on subtractive data analysis of two samples, necessitating identical and 
reproducible sample processing to prevent artificial differences (9) as changes in e.g. peptide 
recovery or chromatographic retention stability can be misinterpreted as altered peptide 
expression. This also holds for a method based on stable isotope labeling of the MHC-
associated peptides after peptide isolation (11). Furthermore as this method is based on the 
determination of intensity ratios within mass spectral doublets, viral epitopes or completely up- 
or down-regulated self-peptides are represented as single spectral peaks, which may hamper 
the recognition of these peptides in complex samples.  
In addition to the qualitative recognition of virally induced peptides, SITE allows the absolute 
quantification of the epitope expression. For up-regulated self-peptides, the epitope quantities 
were revealed by mathematical comparison of the experimental and theoretical isotope 
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distribution patterns indicating the degree of up-regulation of self-peptides (Fig. 1B). This 
method of epitope quantification precludes artificial variances as it is not affected by variations 
in the peptide isolation procedure or chromatographic or mass spectrometric stability because 
the stable isotope labels are incorporated during the viral infection. The degree of up-
regulation is therefore anchored at the moment the control and infected cell batches are 
pooled. The MV epitope KLWESPQEI e.g. (reported earlier at an expression level of >105 
copies/cell (9)) dominated the epitope display at an abundance of 0.5·105 copies/cell after 
infection as calculated from our present experimental data. Furthermore expression levels of 
individual RSV epitopes showed marked differences demonstrated by the HLA-B7-specific 
RSV epitope KARSTPVTL, which was expressed 2.5 times higher than the HLA-A*0201-
specific RSV epitope KLIHLTNAL on infected DCs. Moreover expression levels appeared to 
be influenced by the cell type as illustrated by the epitope KLIHLTNAL, which was expressed 
20 times higher on DCs as compared with epithelial cells.  
In conclusion, application of SITE elucidates the expression of virally induced epitopes and 
induced self-epitopes on HLA class I molecules of several cell types. Applied to this end, SITE 
will attribute to development of antiviral or vaccine strategies that make use of the MHC class 
I route.  
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syncytial virus; RSV-F, RSV fusion protein; RSV-NS, RSV nonstructural protein; SCX, strong 
cation exchange; SITE, stable isotope tagging of epitopes; RRf, relative response factor; 
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